Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Phase 1 Cancer Trials

Alabama

Phase 1 cancer trials in Alabama

36 Phase 1 cancer studies are recruiting participants at sites in 4 cities across Alabama as of November 17, 2026, according to ClinicalTrials.gov.

Call (888) 927-9038
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Every Alabama city with a recruiting study

By research area: Breast Cancer (14), Lymphoma (9), Lung Cancer (7), Melanoma (2), Pancreatic Cancer (2), Prostate Cancer (2).

Birmingham (32), Dothan (2), Huntsville (2), Mobile (1).

The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.

Breast cancer: recently updated in Alabama

Basic details from each study's public record (the 12 most recently updated of 36). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Astellas Pharma Global Development, Inc.
    Recruiting in
    Birmingham
    Registry record
    NCT07488676 · updated
  2. An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    BeOne Medicines
    Recruiting in
    Birmingham
    Registry record
    NCT07222267 · updated
  3. A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Compass Therapeutics
    Recruiting in
    Birmingham
    Registry record
    NCT06150664 · updated
  4. A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Genentech, Inc.
    Recruiting in
    Huntsville
    Registry record
    NCT07100106 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Alabama on ClinicalTrials.gov.

Lung cancer: recently updated in Alabama

  1. Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Boehringer Ingelheim
    Recruiting in
    Birmingham
    Registry record
    NCT04886804 · updated
  2. Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    SystImmune Inc.
    Recruiting in
    Huntsville
    Registry record
    NCT07080242 · updated
  3. FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Gilead Sciences
    Recruiting in
    Birmingham
    Registry record
    NCT06303505 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Alabama on ClinicalTrials.gov.

Prostate cancer: recently updated in Alabama

  1. TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

    • Phase 1/2
    • Ages 18 and older
    • Male participants
    Sponsor
    Novartis Pharmaceuticals
    Recruiting in
    Birmingham
    Registry record
    NCT07190300 · updated
  2. Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

    • Phase 1
    • Ages 18 to 100
    • Male participants
    Sponsor
    Janux Therapeutics
    Recruiting in
    Birmingham
    Registry record
    NCT05519449 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Alabama on ClinicalTrials.gov.

Pancreatic cancer: recently updated in Alabama

  1. A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Artios Pharma Ltd
    Recruiting in
    Birmingham
    Registry record
    NCT04657068 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Alabama on ClinicalTrials.gov.

Ask about studies in Alabama

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 1, including early Phase 1 and combined Phase 1/2, as each study is coded in the registry.

Phase 1 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-9038

or send a short form

How should we reach you?

Call